about
Pharmacotherapies for obesity: past, current, and future therapiesThe use of lorcaserin in the management of obesity: a critical appraisalAnti-Obesity Drugs: A Review about Their Effects and SafetySerotonin 2C receptor activates a distinct population of arcuate pro-opiomelanocortin neurons via TRPC channelsAntiobesity pharmacotherapy: new drugs and emerging targetsTolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.Public health campaigns and obesity - a critiqueSafety of antiobesity drugs.Interleukin-15, IL-15 Receptor-Alpha, and Obesity: Concordance of Laboratory Animal and Human Genetic StudiesComparative efficiency and safety of pharmacological approaches to the management of obesity.Serotonergic anti-obesity agents: past experience and future prospects.Drug treatment of obesity in cardiovascular disease.Treating the obese diabetic.Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Endoscopic Devices for Obesity.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist.
P2860
Q21296814-E8850911-C67C-4003-AE29-BF0274643536Q24594774-7F97D547-F1AC-4671-ABE7-447217AA29A7Q24630947-848915B5-6D01-43B8-B667-95F74964A613Q28585910-F49BE611-27AD-47D2-B6A7-CA0EC137137FQ30354242-2A8642B7-17F6-43E9-B043-9BF5494C20A3Q33570118-4C468ED0-4A7F-4072-9E8D-45E03053FACCQ33830200-F62DAC31-1493-4089-BF2F-215214CE7D71Q34016243-1179DCD5-7280-4EA6-9399-C520D332572CQ34974732-6A792209-AC08-4EDA-B48B-78BC9E1EE37FQ36783891-02EBDDED-0FAF-40AB-B8BF-F2E42FEEDAEDQ37956399-1F1C94F9-CCC1-427F-8173-787DACAEEA4AQ37980171-E5A725D0-CED9-434F-8308-FCB6A10A46C1Q38087696-BAF698E3-2EF1-4061-9B5D-8AB4119CB789Q38308961-BD39F948-232D-4172-8266-51931B169851Q38758765-DA683544-CD59-45D0-8418-19C8EAC178ABQ38817948-7353BCCA-6523-4352-AEEE-4371C9DA2459Q45288843-EB050B92-D052-43CB-BF8D-55D6B3242399Q45908028-82FFB3A4-6984-4E9A-93A7-CC113904BC27
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Drug management of obesity--efficacy versus safety.
@en
Drug management of obesity--efficacy versus safety.
@nl
type
label
Drug management of obesity--efficacy versus safety.
@en
Drug management of obesity--efficacy versus safety.
@nl
prefLabel
Drug management of obesity--efficacy versus safety.
@en
Drug management of obesity--efficacy versus safety.
@nl
P356
P1476
Drug management of obesity--efficacy versus safety.
@en
P304
P356
10.1056/NEJME1004076
P407
P50
P577
2010-07-01T00:00:00Z